Barclays raised the firm’s price target on DexCom to $138 from $115 and keeps an Equal Weight rating on the shares. The company delivered another solid beat and raised guidance for the second time this year, with strength in the business driven by the G7 launch and increased demand among Medicare patients using basal insulin, the analyst tells investors in a research note. DexCom has a number of growth drivers in the second half of 2023 and 2024, but also faces competitive launches, says the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DXCM:
- Early notable gainers among liquid option names on July 28th
- DexCom price target raised to $154 from $140 at Raymond James
- DexCom price target raised to $160 from $150 at Piper Sandler
- DexCom price target raised to $150 from $135 at Oppenheimer
- DexCom price target raised to $150 from $135 at Canaccord